ExaCAR-T

**ExaCAR-T** is an investigational allogeneic CAR-T cell therapy being developed in the Exacis platform that was later brought under Eterna Therapeutics after its 2023 acquisition of Exacis. The product is described as a performance-enhanced, stealthed off-the-shelf T-cell therapy generated using an mRNA-based induced pluripotent stem cell and gene-editing platform that avoids DNA and viral vectors. It is intended for oncology applications across solid and hematologic tumors, but publicly available information does not clearly identify a single antigen-specific ExaCAR-T product or a defined clinical-stage indication. As such, ExaCAR-T is best characterized as a preclinical allogeneic CAR-T cell therapy platform product rather than a marketed or clinically well-defined single-asset drug.

Other names

allogeneic engineered CAR-T cell therapy